Involvement of the GABA-B system in the mechanism of action of ultralow-dose antibodies to S-100 protein

Bulletin of Experimental Biology and Medicine

Volumn 145, Issue 5, 2008, Pages 614-616

  Kheifez, I A ^a   Molodavkin, G M ^a   Voronina, T A ^a   Dugina, Yu L ^a   Sergeeva, S A ^a   Epstein, O I ^a  

^a Materia Medica Holding R   (Russian Federation)

Author keywords

Antibodies to S 100 proteins; Anxiety; Depression; GABAergic system; Ultralow doses

Indexed keywords

4 AMINOBUTYRIC ACID B RECEPTOR; AMITRIPTYLINE; BACLOFEN; DIAZEPAM; PROTEIN ANTIBODY; PROTEIN S 100 ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY DISORDER; ARTICLE; CONTROLLED STUDY; DEPRESSION; GABAERGIC SYSTEM; MALE; NONHUMAN; PROTEIN FUNCTION; RAT; TRANQUILIZING ACTIVITY;

ANIMALS; ANTI-ANXIETY AGENTS; ANTIBODIES; ANTIDEPRESSIVE AGENTS; ANXIETY; BACLOFEN; DEPRESSION; DIAZEPAM; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; GABA AGONISTS; GABA ANTAGONISTS; MALE; RATS; RECEPTORS, GABA-B; S100 PROTEINS;

EID: 55649095709     PISSN: 00074888     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10517-008-0154-y     Document Type: Article

References (15)

1. T. A. Voronina, G. M. Molodavkin, S. A. Sergeeva, and O. I. Epstein, Byull. Eksp. Biol. Med., Suppl. 1, 37-39 (2003).
2. T. A. Voronina, O. I. Epstein, G. M. Molodavkin, et al., Radioekologiya, 43, No. 3, 291-293 (2003).
3. A. V. Kaluev and D. J. Nutt, Eksp. Klin. Farmakol., 67, No. 4, 71-76 (2004).
4. G. M. Molodavkin and T. A. Voronina, Ibid., 58, No. 2, 54-56 (1995).
5. V. P. Fisenko, ed., Manual of Experimental (Preclinical) Studies of New Drugs [in Russian], Moscow (2000).
6. J. F. Cryan, P. H. Kelly, F. Chaperon, et al., J. Pharmacol. Exp. Ther., 310, No. 3, 952-963 (2004).
7. S. J. Enna, Mol. Intervt., 1, No. 4, 208-218 (2001).
8. O. I. Epstein, I. F. Pavlov, and M. B. Shtark, Evid. Based Complement. Alternat. Med., 3, No. 4, 541-545 (2006).
9. R. B. Lydiard, J. Clin. Psychiatry, 64, Suppl. 3, 21-27 (2003).
10. C. B. Nemeroff, Psychopharmacological Bull., 37, No. 4, 133-146 (2003).
11. S. Nomura, J. Shimizu, M. Kinjo, et al., Eur. J. Pharmacol., 83, No. 3-4, 171-175 (1982).
12. D. J. Nutt and A. L. Malizia, Brit. J. Psychiatry, 179, 390-396 (2001).
13. A. Pilc and G. Nowak, Drugs Today (Barc.), 41, No. 11, 755-766 (2005).
14. D. A. Slattery, S. Desrayaud, and J. F. Cryan, J. Pharmacol. Exp. Ther., 312, No. 1, 290-296 (2005).
15. J. Vogel, B. Beer, and D. E. Clody, Psychopharmacologia, 21, No. 1, 1-7 (1971).